Condition: Uveal Melanoma · Sponsor: Inge Marie Svane
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.
This description comes directly from the study's public registry record.
Inge Marie Svane, Professor, MD · 004538683868 · inge.marie.svane@regionh.dk
Tine Juul Monberg, MD, PhD · 004538683868 · tine.monberg@regionh.dk
Always discuss trial participation with your own doctor first.
| National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital | Herlev, Herlev, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07501117